Effects of SGLT2 inhibitors on quality of life in HF.

30 June 2021 (17:05 - 17:11)

Organised by:

Video

Sign in to view the resources

About the speaker

Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

5 More presentations in this session

Presentation thumbnail

Introduction: SGLT2 inhibitors beyond glycemic control.

Doctor S. Zieroth (Winnipeg, CA)

Presentation thumbnail

Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.

Professor M. Packer (Dallas, US)

Presentation thumbnail

Renal benefits of SGLT2 inhibitors in HF patients.

Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Presentation thumbnail

Safety of SGLT2 inhibitors with a focus on genital mycotic infections.

Professor G. Filippatos (Athens, GR)

Presentation thumbnail

Conclusion.

Professor S. Anker (Berlin, DE)

Access the full session

Session thumbnail

SGLT2 inhibition in heart failure: what have we learned so far?

The Event

Heart Failure 2021

30 June 2021 17:05 CET

You may be interested in

Congress Session

Heart Failure 2025 highlights

Congress Presentation

Fetal recapitulation and cellular stress in the evolution and progression of heart failure

Congress Session

Unspoken aetiologies of heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources